Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

The authors concluded that increasing regulatory T cells in patients with alopecia areata may improve hair follicle regeneration by reducing autoimmune responses, suggesting a potential new therapeutic approach since current treatments are often ineffective with high relapse rates.

This review hypothesizes that excessive facial photo-protection may contribute to frontal fibrosing alopecia by disrupting immunological homeostasis through the aryl hydrocarbon receptor-kynurenine pathway, but it reports no new clinical results.

This review suggests that excessive facial photoprotection could play a role in frontal fibrosing alopecia through a disturbance in immunological balance via the aryl hydrocarbon receptor-kynurenine pathway.

This review examines the immunological aspects of alopecia areata, focusing on genetic, neuroimmunological, and immune privilege factors, but does not report new clinical findings.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

This study used a mouse model to enhance understanding of alopecia pathogenesis and suggested a therapeutic strategy for managing inflammation in EGFR-inhibitor therapy-induced folliculitis and cicatricial alopecia.

This study concluded that the CXCL12–CXCR4 signaling pathway significantly contributes to hair loss in androgenetic alopecia and alopecia areata by promoting inflammation and fibrosis, whereas inhibiting this pathway can restore hair growth and follicle health.

This study suggests that sweat glands may have an immune privilege similar to hair follicles, and disruptions in this could contribute to autoimmune skin diseases.

This review discusses the pathogenesis and challenges in treating primary cicatricial alopecia, highlighting the need to understand immune protection collapse in hair follicle stem cells; it reports no new clinical results.

This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.

This review discusses recent advancements in nanotechnology for treating hypertrophic scarring and atopic dermatitis, highlighting the potential of nanotherapeutic platforms in enhancing therapeutic effects by modulating the skin's microenvironment.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

This review discusses fibrosing frontal alopecia, including its causes, mechanisms, and treatments, and emphasizes the need for further research to improve understanding and treatments; it reports no new clinical results.

This review discusses the association between oxidative stress and alopecia areata while proposing antioxidants as a potential supplementary therapy, but it reports no new clinical results.

Winter-onset alopecia areata patients are more likely to regrow hair within a year compared to spring-onset patients.

This study suggests that rather than inhibiting IL-15, selectively stimulating IL-15Ra-mediated signaling could be beneficial for managing alopecia areata and possibly other inflammatory hair loss conditions, as IL-15 promoted hair growth and maintained immune privilege in human hair follicles.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This study found that immune privilege collapse in the hair follicle bulge and associated immune responses may contribute significantly to the pathogenesis of lichen planopilaris, suggesting a potential autoimmune basis for the disease.

This review highlights emerging evidence that chemotherapy-induced alopecia may be driven by immune mechanisms similar to alopecia areata, involving hair follicle immune privilege collapse, and evaluates Janus kinase inhibitors as potential treatments, while cautioning about their immunosuppressive risks in cancer patients.

In this review, researchers discussed the anti-inflammatory and immunomodulatory properties of metformin and hypothesized that its topical application could benefit those with alopecia areata, given its effects on immune pathways, hair regrowth, and autoimmune disease management.

This study found that gene expression of CD70 and CD27 was higher in alopecia areata lesions and correlated with increased disease severity and activity.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This review explored the relationship between autoimmune thyroiditis and various autoimmune skin conditions, highlighting shared genetic markers and immunological mechanisms, such as disrupted immune tolerance and oxidative stress, which may contribute to the development of these disorders.

This case report discusses a young woman who developed bilateral osteonecrosis of the femoral head after corticosteroid treatment for alopecia areata, underscoring the risk of this complication in patients undergoing such therapy.

This report from the seventh AA Research Summit discusses research highlights and sets future priorities for managing alopecia areata.

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.